Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study

    March 2026 in “ American Journal of Clinical Dermatology ”
    Michela Starace, Luca Rapparini, Francesca Pampaloni … Bianca Maria Piraccini
    Studysummary In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 23

    1. Real-World Assessment of Ritlecitinib in Patients with Severe Alopecia Areata: A 24-Week Multicentre Retrospective Study Clinical and Experimental Dermatology · 2025
    2. Alopecia Areata: Pathogenesis, Diagnosis, And Therapies MedComm · 2025
    3. Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The Allegro Phase 2b/3 Randomized Clinical Trial American Journal of Clinical Dermatology · 2024
    4. Efficacy and Safety of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, in Adolescent and Adult Patients with Alopecia Totalis and Alopecia Universalis The Journal of Dermatology · 2024
    5. Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study Journal of the European Academy of Dermatology and Venereology · 2024
    6. Assessment of Clinician-Reported Outcome Measures for Alopecia Areata: A Systematic Scoping Review Clinical and Experimental Dermatology · 2024
    7. Italian National Registry of Alopecia Areata: An Epidemiological Study of 699 Italian Patients Italian Journal of Dermatology and Venereology · 2024
    8. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    9. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    10. Ritlecitinib: First Approval Drugs · 2023
    11. Janus Kinase Inhibitors for Alopecia Areata Journal of the American Academy of Dermatology · 2023
    12. Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial Pediatric Dermatology · 2023
    13. Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials Journal of dermatological treatment · 2023
    14. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    15. Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2023
    16. Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2022
    17. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata Drug Design Development and Therapy · 2022
    18. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    19. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    20. Common Causes of Hair Loss: Clinical Manifestations, Trichoscopy, and Therapy Journal of the European Academy of Dermatology and Venereology · 2020
    21. Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata American Journal of Clinical Dermatology · 2020
    22. Italian Guidelines in Diagnosis and Treatment of Alopecia Areata Giornale italiano di dermatologia e venereologia · 2019
    23. Investigative Guidelines for Alopecia Areata Dermatologic therapy · 2011